Risk Factors for Anemia in CKD: Review and Meta-Analysis
Anemia associated with chronic kidney disease (CKD) has significant impact on patients, healthcare systems, and financial resources. Ping Yin, MB, and colleagues conducted a...
Post Hoc Analysis: Factors Affecting Doses of Roxadustat versus Darbepoetin Alfa
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). Tadao Akizawa, MD, PhD, and...
Review and Meta-Analysis: Roxadustat for Treatment of Anemia in CKD
Chronic kidney disease (CKD) is commonly associated with renal anemia. Roxadustat is the first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of...
Variations in Health Plan Coverage of ESAs for Anemia in CKD
NikoLetta M. Margaretos, BA, and colleagues conducted a study to examine policies among commercial health plans for coverage of erythropoiesis-stimulating agents (ESAs) for patients...
Best of the International Myeloma Workshop with Dr. Manni Mohyuddin
Greetings, DocWire News readers. I attempt here to summarize the most important updates from the 2021 International Myeloma Workshop (IMW) meeting. I will try...
Blood Cancer Awareness Month Spotlights Hematologic Cancers
Did you know September is Blood Cancer Awareness Month? This month, take the time to learn more about this disease, which impacts more than...
Vadadustat for Anemia in Patients with Chronic Kidney Disease
Anemia is a common complication of chronic kidney disease (CKD) and is associated with a reduced health-related quality of life, an increase in the...
